Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT: Difference between revisions
Aysha Aslam (talk | contribs) |
Aysha Aslam (talk | contribs) |
||
Line 66: | Line 66: | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Oral beta blockers, diltiazem, or verapamil are indicated for ongoing management of AVRT in patients without | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Oral [[beta blockers]], [[diltiazem]], or [[verapamil]] are indicated for ongoing management of AVRT in patients without pre-excitation on their resting ECG <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | ||
pre-excitation on their resting ECG <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | |||
|} | |} |
Revision as of 16:15, 27 October 2016
Supraventricular tachycardia Microchapters |
Differentiating Among the Different Types of Supraventricular Tachycardia |
---|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
Diagnosis |
Treatment |
2015 ACC/AHA Guideline Recommendations |
Case Studies |
Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT On the Web |
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
FDA on Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
CDC on Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT in the news |
Blogs on Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT |
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Management of Orthodromic AVRT
2015 AHA recommendations for the management of the acute and ongoing treatment for the orthodromic AVRT are described below:[1]
Acute Treatment of Orthodromic AVRT
Class I |
"1. Vagal maneuves are recommended for acute treatment in patients with orthodromic AVRT "(Level of Evidence: B-R) " |
"2. Adenosine is beneficial for acute treatment in patients with orthodromic AVRT "(Level of Evidence: B-R) " |
"3. Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with
AVRT if vagal maneuvers or adenosine are ineffective or not feasible "(Level of Evidence: B-NR) " |
"4. Synchronized cardioversion is recommended for acute treatment in hemodynamically stable patients with AVRT
when pharmacological therapy is ineffective or contraindicated "(Level of Evidence: B-NR) " |
"5. Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with
pre-excited AF"(Level of Evidence: B-NR ) " |
"6. Ibutilide or intravenous procainamide is beneficial for acute treatment in patients with pre-excited AF
who are hemodynamically stable "(Level of Evidence: C-LD) " |
Class IIa |
"1. Intravenous diltiazem, verapamil "(Level of Evidence: B-R) or beta blockers can be effective for acute treatment in patients with orthodromic AVRT who do not have preexcitation on their resting ECG during sinus rhythm "(Level of Evidence: C-LD) " |
Class IIb |
"1. Intravenous beta blockers, diltiazem, or verapamil might be considered for acute treatment in patients with orthodromic AVRT who have pre-excitation on their resting ECG and have not responded to other therapies (Level of Evidence:B-R) " |
Class III(harm) |
"1. Intravenous digoxin, intravenous amiodarone, intravenous or oral beta blockers, diltiazem, and verapamil are
potentially harmful for acute treatment in patients with pre-excited AF (Level of Evidence: C-LD) " |
Management of ongoing Orthodromic AVRT
Class I |
"1. Catheter ablation of the accessory pathway is recommended in patients with AVRT and/or pre-excited AF"(Level of Evidence: B-NR) " |
"2. Oral beta blockers, diltiazem, or verapamil are indicated for ongoing management of AVRT in patients without pre-excitation on their resting ECG "(Level of Evidence: C-LD) " |
Class IIa |
"1. Oral flecainideor propafenone is reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have AVRT and/or pre-excited AF and are not candidates for, or prefer not to undergo, catheter ablation"(Level of Evidence: C-LD) " |
Class IIb |
"1. Oral dofetilide or sotalol may be reasonable for ongoing management in patients with AVRT and/or pre-excited AF who are not candidates for, or prefer not to undergo, catheter ablation" (Level of Evidence:B-R) " |
"2. Oral amiodarone may be considered for ongoing management in patients with AVRT and/or pre-excited AF who are not candidates for, or prefer not to undergo, catheter ablation and in whom beta blockers, diltiazem, flecainide, propafenone, and verapamil are ineffective or contraindicated"(Level of Evidence:C-LD) " |
References
- ↑ Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ; et al. (2016). "2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol. 67 (13): e27–e115. doi:10.1016/j.jacc.2015.08.856. PMID 26409259.